Agenda for the 22 June 2016 TC meeting

16 June 2016 - The Transparency Commission will consider the reimbursement of glatiramer acetate (Copaxone), ruxolitinib phosphate (Jakavi), clobazam (Likozam) and ...

Read more →

Agenda for the 8 June 2016 TC meeting

1 June 2016 - The Transparency Commission will consider the (continued) reimbursement of dexketoprofen with tramadol hydrochloride (Skudexum), empagliflozin (Jardiance), plasma ...

Read more →

Agenda for the 25 May 2016 TC meeting

22 May 2016 - The Transparency Commission will consider the (continued) reimbursement of voriconazole (Vfend), belatacept (Nulojix), bevacizumab (Avastin), bicalutamide (Casodex), ...

Read more →

Agenda for the 11 May 2016 TC meeting

5 May 2016 - The Transparency Commission will consider the reimbursement of golimumab (Simponi), metyrapone (Metyrapone HRA Pharma) and tiotropium bromide ...

Read more →

France gets G7 to discuss global regulation of medicine prices

2 May 2016 - France will press its G7 partners this month to launch an "irreversible" process to control the prices ...

Read more →

Agenda for the 20 April 2016 TC meeting

13 April 2016 - The Transparency Commission will consider the reimbursement of Wakix (pitolisant), Busilvex (busulphan), Cosentyx (secukinumab), Anoro Ellipta (vilanterol ...

Read more →

Agenda for the 13 April 2016 TC meeting

12 April 2016 - The Transparency Commission will consider the reimbursement of Praxbind (idarucizumab) and Xalatan (latanoprost). The Commission will also ...

Read more →

Agenda for the 6 April 2016 TC meeting

31 March 2016 - The Transparency Commission will consider the reimbursement of pertuzumab (Perjeta), lixisenatide (Lyxumia), ezetimibe (Ezetrol) and secukinumab (Cosentyx). ...

Read more →

France to call for lower drug prices at G7

22 March 2016 - France will announce a campaign to lower the price of new medicines, hoping world powers at the ...

Read more →

Agenda for the 16 March 2016 TC meeting

9 March 2016 - The Transparency Commission will consider the reimbursement of ceftolozane sulphate with tazobactam sodium (Zerbaxa), lumacaftor with ivacaftor ...

Read more →

Agenda for the 2 March 2016 TC meeting

1 March 2016 - The Transparency Commission will consider the reimbursement of daclatasvir dihydrochloride (Daklinza), ustekinumab (Stelara), radium Ra 223 dichloride ...

Read more →

Agenda for the 17 February 2016 TC meeting

11 February 2016 -  The Transparency Commission will consider the reimbursement of sonidegib diphosphate (Odomzo), emtricitabine with elvitegravir and cobicistat and ...

Read more →

Agenda for the 3 February 2016 TC meeting

29 January 2016 - The Transparency Commission will consider the reimbursement of sufentanil (Zalviso), efmoroctocog alfa (Elocto) and asfotase alfa (Stensiq). ...

Read more →

Agenda for the 20 January 2016 TC meeting

18 January 2016 - The Transparency Commission will consider the reimbursement of dronedarone hydrochloride (Multaq), palonosetron hydrochloride (AloxI), lanreotide acetate ...

Read more →

Agenda for the 6 January 2016 TC meeting

31 December 2015 - The Transparency Commission will consider the reimbursement of adalimumab (Humira), delamanid (Deltyba), panobinostat lactate (Farydak), lenalidomide (Revlimid) ...

Read more →